Literature DB >> 15890553

Improved protection by recombinant BCG.

Ali Nasser Eddine1, Stefan H E Kaufmann.   

Abstract

Mycobacterium bovis bacille Calmette Guérin (BCG) is one of the most widely used live vaccines. Technologic advancement in genome manipulation enables the construction of recombinant BCG (rBCG) strains, which can be employed as highly immunogenic vaccines against tuberculosis with improved safety profile.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15890553     DOI： 10.1016/j.micinf.2005.03.012

Source DB:  PubMed          Journal:  Microbes Infect        ISSN： 1286-4579            Impact factor:   2.700


  9 in total

1.  Protection of mice from Mycobacterium tuberculosis by ID87/GLA-SE, a novel tuberculosis subunit vaccine candidate.

Authors:  Hillarie Plessner Windish; Malcolm S Duthie; Ayesha Misquith; Greg Ireton; Elyse Lucas; John D Laurance; Remy H Bailor; Rhea N Coler; Steven G Reed
Journal:  Vaccine       Date:  2011-08-02       Impact factor: 3.641

2.  Recombinant Mycobacterium bovis BCG expressing the chimeric protein of antigen 85B and ESAT-6 enhances the Th1 cell-mediated response.

Authors:  Ying Xu; Wei Liu; Hongbo Shen; Jingran Yan; Di Qu; Honghai Wang
Journal:  Clin Vaccine Immunol       Date:  2009-06-10

3.  Protective efficacy of a recombinant BCG secreting antigen 85B/Rv3425 fusion protein against Mycobacterium tuberculosis infection in mice.

Authors:  Jiuling Wang; Yaqing Qie; Wei Liu; Honghai Wang
Journal:  Hum Vaccin Immunother       Date:  2012-08-21       Impact factor: 3.452

4.  Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon.

Authors:  Katarina Radosevic; Catharina W Wieland; Ariane Rodriguez; Gerrit Jan Weverling; Ratna Mintardjo; Gert Gillissen; Ronald Vogels; Yasir A W Skeiky; David M Hone; Jerald C Sadoff; Tom van der Poll; Menzo Havenga; Jaap Goudsmit
Journal:  Infect Immun       Date:  2007-05-25       Impact factor: 3.441

5.  Recombinant Mycobacterium bovis bacillus Calmette-Guerin elicits human immunodeficiency virus type 1 envelope-specific T lymphocytes at mucosal sites.

Authors:  Jae-Sung Yu; James W Peacock; William R Jacobs; Richard Frothingham; Norman L Letvin; Hua-Xin Liao; Barton F Haynes
Journal:  Clin Vaccine Immunol       Date:  2007-05-16

6.  MicroRNA-155 is required for Mycobacterium bovis BCG-mediated apoptosis of macrophages.

Authors:  Devram Sampat Ghorpade; Rebecca Leyland; Mariola Kurowska-Stolarska; Shripad A Patil; Kithiganahalli Narayanaswamy Balaji
Journal:  Mol Cell Biol       Date:  2012-04-02       Impact factor: 4.272

7.  Modulation of humoral immune response to oral BCG vaccination by Mycobacterium bovis BCG Moreau Rio de Janeiro (RDJ) in healthy adults.

Authors:  Renata Monteiro-Maia; Maria B Ortigão-de-Sampaio; Rosa T Pinho; Luiz R R Castello-Branco
Journal:  J Immune Based Ther Vaccines       Date:  2006-09-06

Review 8.  Live bacterial vaccine vectors: an overview.

Authors:  Adilson José da Silva; Teresa Cristina Zangirolami; Maria Teresa Marques Novo-Mansur; Roberto de Campos Giordano; Elizabeth Angélica Leme Martins
Journal:  Braz J Microbiol       Date:  2015-03-04       Impact factor: 2.476

9.  Recombinant Bacille Calmette-Guérin coexpressing Ag85B-IFN-γ enhances the cell-mediated immunity in C57BL/6 mice.

Authors:  Wei Liu; Ying Xu; Hongbo Shen; Jingran Yan; Enzhuo Yang; Honghai Wang
Journal:  Exp Ther Med       Date:  2017-03-28       Impact factor: 2.447
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.